The Department of Radiology and RevealDx also agreed to expand their research to evaluate
RevealAI-Lung for clinical use in Lung Cancer Screening and incidentally found nodules
Seattle, WA – November 9, 2022 – RevealDx announced today that their first installation of
RevealAI-Lung in Europe, at the Royal United Hospitals Bath NHS Foundation Trust, has yielded
positive results when used to help assess lung nodules found to be at high risk. The department
of Radiology intends to expand the research to evaluate the system for use in Lung Cancer
Screening as well as management of incidentally found nodules.
RevealDx developed RevealAI-Lung, the world’s first CADx software for the characterization of
lung nodules to receive CE Mark. The company recently published its pivotal research study
which demonstrated significant improvement in both early identification of malignant nodules and
reduction in false positive nodules in both screening and incidental cohorts. By integrating this
patented technology into clinical routine, healthcare providers can reduce unnecessary
procedures, cost and stress for patients with lung nodules.
Royal United Hospitals Bath NHS evaluated the performance of RevealAI-Lung in a retrospective
study of high-risk patients. Use of RevealAI-Lung would have prevented unnecessary follow-up
and flagged cancers early in these patients. Because the results could be of interest to other
researchers and clinical sites, this work will be submitted for publication. Following the success of
this research, RUH Bath is expanding analysis to additional populations, and looks forward to the
planned installation for clinical use.
About RevealDx
RevealDx developed RevealAI-Lung, the world’s first CADx software for the characterization of
lung nodules to receive the CE Mark. RevealAI-Lung has been validated in clinical studies that
show improvement in diagnostic precision using our patented methods. Results demonstrate the
software can significantly accelerate lung cancer diagnosis and reduce unnecessary procedures.